ScreenerHero

CAMPCalAmp Corp.

NAS · US · Technology · Biotechnology · camp4tx.com
4.480USD-3.66%Mkt Cap: 281.13M $P/E: —

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap281.13M $
Enterprise Value195.85M $
Revenue (TTM)4.22M $
Gross Profit-34.47M $
Net Income (TTM)-80.40M $
Revenue/Share0.0860 USD
Last Price4.480 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees48
CountryUS
SectorTechnology
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.61
PEG—
EV/EBITDA-3.87
EV/Revenue46.45
P/S66.39
P/B-343.08
EPS (TTM)-2.21
EPS (Forward)-0.79
52W Range
1.41048% of range7.750
52W High7.750 USD
52W Low1.410 USD
Profitability
Gross Margin0.00%
Oper. Margin-752.11%
EBITDA Margin0.00%
Profit Margin-2298.54%
ROE-168.55%
ROA-68.25%
Growth
Revenue Growth18.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.55M $
CapEx (TTM)279.00K $
FCF Margin-304.27%
FCF Yield-4.56%
Net Debt-84.03M $
Net Debt/EBITDA1.66
Balance Sheet
Debt/Equity0.04
Current Ratio4.70
Quick Ratio4.53
Book Value/Sh-0.0130 USD
Cash/Share1.377 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.917 USD
Upside (mean)+121.4%
Target Range6.500 USD – 15.00 USD
$6.500+121.4% to mean$15.00
# Analysts6
Ownership
Shares Out.62.75M
Float37.87M
Insiders9.65%
Institutions79.59%
Short Interest
Short Ratio8.4d
Short % Float4.22%
Short % Out.2.85%
Shares Short1.48M
Short (prev mo.)1.31M
Technical
SMA 504.110 (+9.0%)
SMA 2004.479 (+0.0%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)214.44K
Avg Vol (10d)253.22K
Technical Indicators
RSI (14)53.3
MACD0.2175
MACD Signal0.1814
MACD Hist.+0.0361
BB Upper5.396 USD
BB Middle4.225 USD
BB Lower3.054 USD
BB Width55.42%
ATR (14)0.4528 USD
Vol Ratio (20d)0.55x